首页 | 官方网站   微博 | 高级检索  
     

8种胃癌化疗药物与药品不良反应的聚类关系分析
引用本文:郭佳栋,张雪梅,刘影,冯变玲. 8种胃癌化疗药物与药品不良反应的聚类关系分析[J]. 中国药事, 2017, 31(5): 584-590
作者姓名:郭佳栋  张雪梅  刘影  冯变玲
作者单位:西安交通大学药学院药事管理与临床药学系, 西安 710061;西安交通大学药品安全与政策研究中心, 西安 710061,西安交通大学药学院药事管理与临床药学系, 西安 710061;西安交通大学药品安全与政策研究中心, 西安 710061,西安交通大学药学院药事管理与临床药学系, 西安 710061;西安交通大学药品安全与政策研究中心, 西安 710061,西安交通大学药学院药事管理与临床药学系, 西安 710061;西安交通大学药品安全与政策研究中心, 西安 710061
基金项目:国家社科基金资助项目(编号13BGL132);陕西省社会发展科技攻关项目(编号2016SF-159)
摘    要:目的:分析胃癌化疗药物不良反应与药品品种间的聚类关系,促进临床安全合理用药。方法:收集109家药品生产企业2010-2014年生产的8种胃癌化疗药物氟尿嘧啶、卡培他滨、表柔比星、顺铂、伊立替康、紫杉醇、奥沙利铂和多西他赛的不良反应报告数据,运用数据挖掘技术对药品不良反应与药品品种间的关系进行聚类分析,使用Clementine 14.1软件进行统计。结果与结论:共收集有效报告10572份,卡培他滨和顺铂,表柔比星和伊立替康,多西他赛和紫杉醇联合用药发生一般药品不良反应的可能性较大。卡培他滨、顺铂、伊立替康和表柔比星联合用药;多西他赛、氟尿嘧啶和紫杉醇联合用药时,出现严重药品不良反应的概率较高。瘙痒、过敏性休克、顺铂、多西他赛在聚类过程中的运算比重较大。

关 键 词:药品不良反应  胃癌化学药物  氟尿嘧啶  卡培他滨  表柔比星  顺铂  伊立替康  紫杉醇  奥沙利铂  多西他赛  聚类关系  数据挖掘
收稿时间:2016-05-31

Cluster Analysis of Eight Kinds of Gastric Cancer Drugs and Adverse Drug Reactions
Guo jiadong,Zhang Xuemei,Liu Ying and Feng Bianling. Cluster Analysis of Eight Kinds of Gastric Cancer Drugs and Adverse Drug Reactions[J]. Chinese Pharmaceutical Affairs, 2017, 31(5): 584-590
Authors:Guo jiadong  Zhang Xuemei  Liu Ying  Feng Bianling
Affiliation:The Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi''an Jiaotong University, Xi''an 710061, China;The Center for Drug Safety and Policy Research, Xi''an Jiaotong University, Xi''an 710061, China,The Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi''an Jiaotong University, Xi''an 710061, China;The Center for Drug Safety and Policy Research, Xi''an Jiaotong University, Xi''an 710061, China,The Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi''an Jiaotong University, Xi''an 710061, China;The Center for Drug Safety and Policy Research, Xi''an Jiaotong University, Xi''an 710061, China and The Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi''an Jiaotong University, Xi''an 710061, China;The Center for Drug Safety and Policy Research, Xi''an Jiaotong University, Xi''an 710061, China
Abstract:Objective: To find the potential cluster relationship between drugs and adverse drug reactions, so as to build the cluster model and guide the clinical drug use. Methods: Reports of adverse reactions caused by 8 kinds of gastric cancer drugs were collected from 109 pharmaceutical producing enterprises during 2010-2014, including fluorouracil, capecitabine, epirubicin, irinotecan, cisplatin, paclitaxel, oxaliplatin and docetaxel. Data mining technology was used to build cluster model and clementine 14.1 was for statistical analysis. Results and conclution: 10,572 effective reports were collected and statistically analyzed, which showed that capecitabine combined with cisplatin, epirubicin with irinotecan, and docetaxel with paclitaxel were more likely to cause general adverse drug reactions. The combination of capecitabine, cisplatin, irinotecan and epirubicin, as well as the combination of docetaxel, fluorouracil and paclitaxel, was more likely to cause serious adverse drug reactions. Pruritus, anaphylactic, cisplatin and docetaxel were more important in the process of cluster analysis.
Keywords:adverse drug reactions   gastric cancer chemotherapy drug   fluorouracil   capecitabine   epirubicin   irinotecan   cisplatin   paclitaxel   oxaliplatin   docetaxel   cluster analysis   data mining
点击此处可从《中国药事》浏览原始摘要信息
点击此处可从《中国药事》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号